CLINICAL TRIALS PROFILE FOR AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE

All Clinical Trials for AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04901117 ↗	Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days	Not yet recruiting	Heze Municipal 3rd people's hospital	Phase 4	2021-06-01	The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.
NCT04901117 ↗	Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days	Not yet recruiting	Jining No.2 People's Hospital	Phase 4	2021-06-01	The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.
NCT04901117 ↗	Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days	Not yet recruiting	Maternity and Child Care Health Center of Dezhou	Phase 4	2021-06-01	The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.
NCT04901117 ↗	Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days	Not yet recruiting	PKUcare luzhong hospital	Phase 4	2021-06-01	The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.
NCT04901117 ↗	Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days	Not yet recruiting	Qihe County City Hospital	Phase 4	2021-06-01	The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.
NCT04901117 ↗	Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days	Not yet recruiting	Qilu Hospital of Shandong University	Phase 4	2021-06-01	The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.
NCT04901117 ↗	Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days	Not yet recruiting	Shandong Electric Power Central Hospital	Phase 4	2021-06-01	The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.

Clinical Trial Conditions for AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE

Condition Name

Condition Name for AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE
Intervention	Trials
Helicobacter Pylori Infection	2
Helicobacter Infection	1
Helicobacter Pylori Gastrointestinal Tract Infection	1
Helicobacter Pylori Infected Patients	1

Condition MeSH

Condition MeSH for AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE
Intervention	Trials
Helicobacter Infections	1

Clinical Trial Locations for AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE

Trials by Country

Trials by Country for AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE
Location	Trials
China	3

Clinical Trial Progress for AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE

Clinical Trial Phase

Clinical Trial Phase for AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE
Clinical Trial Phase	Trials
PHASE2	1
Phase 4	2

Clinical Trial Status

Clinical Trial Status for AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE
Clinical Trial Phase	Trials
Not yet recruiting	1
NOT_YET_RECRUITING	1
Recruiting	1

Clinical Trial Sponsors for AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE

Sponsor Name

Sponsor Name for AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE
Sponsor	Trials
Shandong University	2
Heze Municipal 3rd people's hospital	2
Maternity and Child Care Health Center of Dezhou	2

Sponsor Type

Sponsor Type for AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE
Sponsor	Trials
Other	22

Clinical Trials, Market Analysis, and Projection for Amoxicillin, Clarithromycin, and Vonoprazan Fumarate

Last updated: February 20, 2026

What is the current status of clinical trials for Amoxicillin, Clarithromycin, and Vonoprazan Fumarate?

Amoxicillin and Clarithromycin are longstanding antibiotics with well-established clinical use. Both have a vast history of clinical trials, primarily focused on bacterial infections such as otitis media, pneumonia, and Helicobacter pylori eradication.

Vonoprazan Fumarate, a potassium-competitive acid blocker (P-CAB), is a newer agent approved for gastroesophageal reflux disease (GERD) and H. pylori eradication in select markets, notably Japan. Its clinical development includes trials comparing efficacy and safety against traditional proton pump inhibitors (PPIs).

Clinical Trial Landscape (2020–2023)

Drug	Number of trials	Top indications	Registration status	Key clinical trial milestones
Amoxicillin	Over 50 ongoing or completed trials	Bacterial infections, H. pylori	Widely approved, multiple generics	No recent pivotal trials; focus on combination therapies
Clarithromycin	Over 30 ongoing or completed trials	H. pylori, respiratory infections	Extensive approval worldwide	Several trials testing resistance management
Vonoprazan Fumarate	Over 15 ongoing trials	GERD, H. pylori, erosive esophagitis	Approved in Japan; Phase III in international sites	Recent phase III results demonstrate non-inferiority to PPIs

Sources: ClinicalTrials.gov, 2023 data.

Market Analysis: Size, Growth Drivers, and Competitive Position

Market Size (2022)	Drug	Global Market ($ billions)	Key Regions	Major competitors	Market share estimates
Amoxicillin	4.5	North America, Europe, Asia	Penicillin, Amoxicillin-clavulanate	35% of antibiotic sales
Clarithromycin	1.8	North America, Europe, Asia	Azithromycin, other macrolides	20% of macrolide segment
Vonoprazan Fumarate	0.3 (Japan only), $1.2 (Global potential)	Japan, Korea, Emerging markets	PPIs (omeprazole, esomeprazole)	Limited but growing

Drivers

• Increasing antibiotic resistance challenges for clarithromycin.
• Rising demand for novel acid suppressants like vonoprazan due to efficacy and safety profile.
• Aging populations increasing prevalence of gastrointestinal and respiratory conditions.

Challenges

• Antibiotic resistance reducing amoxicillin and clarithromycin efficacy.
• Strict regulatory environments impacting new market entries.
• Patent expirations for older antibiotics lowering revenues.

Market Projection (2023–2030)

Drug	Projected CAGR	2030 Market Size	Influencing Factors
Amoxicillin	2.5%	$5.2 billion	Generics dominate, slight growth
Clarithromycin	1.8%	$2.0 billion	Resistance management, patent expiry in some regions
Vonoprazan Fumarate	8.0%	$2.0 billion	Expansion into global markets, new indications

Assumptions:

• Continued resistance limits growth for clarithromycin.
• Vonoprazan's international approval could accelerate global uptake.
• Amoxicillin's market stabilizes with few novel formulations.

Competitive Dynamics and Strategic Implications

• Amoxicillin maintains leadership through generics, with minimal R&D activity.
• Clarithromycin faces declining efficacy due to resistance, requiring reformulation or combination therapies.
• Vonoprazan represents a disruptor, competing directly with PPIs, especially in Japan and Asia.

Market Entry Opportunities

• Innovating existing antibiotics with enhanced delivery or resistance mitigation.
• Expanding vonoprazan to markets outside Japan, including North America and Europe.
• Developing combination regimens for H. pylori and other infections.

Key Takeaways

• Amoxicillin and clarithromycin hold dominant positions in antibiotics but face headwinds from resistance and patent expiry.
• Vonoprazan fumarate shows promising growth prospects driven by superior efficacy and safety profile.
• Global markets for antibiotics remain mature, with subject to regulatory, resistance, and supply challenges.
• Faster approval pathways and strategic partnerships will influence position, especially for vonoprazan internationally.
• Long-term growth depends on pharmaceutical innovation to counteract resistance and expand indications.

FAQs

1. Is vonoprazan approved outside Japan?

Currently, vonoprazan is approved only in Japan. Clinical trials are ongoing in multiple countries, including the US and Europe, aiming for approval.

2. How is antibiotic resistance impacting the market?

Resistance reduces the effectiveness of drugs like clarithromycin and amoxicillin, leading to increased demand for new agents or combination therapies.

3. Are there new formulations of amoxicillin in development?

Most innovation involves combination formulations or extended-release products, rather than new molecules, due to the mature market.

4. What are the main competitors to vonoprazan?

PPIs like omeprazole and esomeprazole are primary competitors, with new P-CABs emerging as alternatives.

5. What is the outlook for the global market for these drugs?

Steady growth expected for amoxicillin and clarithromycin markets, constrained by resistance and patent issues. Vonoprazan's market potential is substantial if international approvals are secured.

---

Sources

1. ClinicalTrials.gov. (2023). Summary of trials for amoxicillin, clarithromycin, and vonoprazan.
2. MarketsandMarkets. (2022). Antibiotics and gastric acid suppressant market analysis.
3. IQVIA. (2022). Global pharmaceutical sales data.
4. Japan Ministry of Health, Labour and Welfare. (2022). Vonoprazan approval and sales figures [in Japanese].

---